Arffman M, Meriranta L, Autio M, Holte H, Jørgensen J, Brown P, Jyrkkiö S, Jerkeman M, Drott K, Fluge Ø, Björkholm M, Karjalainen-Lindsberg ML, Beiske K, Pedersen MØ, Leivonen SK, Leppä S(2024) Inflammatory and subtype-dependent serum protein signatures predict survival beyond the ctDNA in aggressive B cell lymphomas Med, 5(6), 583-602.e5 DOI 10.1016/j.medj.2024.03.007, PubMed 38579729
Borchmann P, Ferdinandus J, Schneider G, Moccia A, Greil R, Hertzberg M, Schaub V, Hüttmann A, Keil F, Dierlamm J, Hänel M, Novak U, Meissner J, Zimmermann A, Mathas S, Zijlstra JM, Fosså A, Viardot A, Hertenstein B, Martin S, Giri P, Scholl S, Topp MS, Jung W, Vucinic Vet al.(2024) Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial Lancet(in press) DOI 10.1016/S0140-6736(24)01315-1, PubMed 38971175
Damek A, Kurch L, Franke FC, Attarbaschi A, Beishuizen A, Cepelova M, Ceppi F, Daw S, Dieckmann K, Fernández-Teijeiro A, Feuchtinger T, Flerlage JE, Fosså A, Georgi TW, Hasenclever D, Hraskova A, Karlen J, Klekawka T, Kluge R, Körholz D, Landman-Parker J, Leblanc T, Mauz-Körholz C, Metzler M, Pears Jet al.(2024) Hodgkin lymphoma: hypodense lesions in mediastinal masses Sci Rep, 14(1), 14591 DOI 10.1038/s41598-024-64253-8, PubMed 38918503
